Denali Therapeutics Inc. Stock Analysis & AI Score
Denali Therapeutics Inc. (DNLI) has an ST Score of 45.3 (C+), driven by its Forecast (B+) and held back by its Growth (D). Analysts rate it Buy with a $33.67 price target (+64.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Denali Therapeutics Inc. (DNLI) has an ST Score of 45.3 (C+), driven by its Forecast (B+) and held back by its Growth (D). Analysts rate it Buy with a $33.67 price target (+64.5% upside).
- Strongest
- ForecastB+
- Weakest
- GrowthD
All factor grades
- ForecastB+
- Financial StrengthB-
- ProfitabilityC+
- MomentumC+
- ValuationC
- GrowthD
- Piotroski3/9
Contact
DNLI stock: frequently asked questions
What is DNLI's ST Score?
Denali Therapeutics Inc. (DNLI) has an ST Score of 45.3 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is DNLI a buy, hold, or sell?
Analysts rate DNLI a Buy, with a price target of $33.67 (+64.5% vs the current price). Our ST Score grades it C+ (45.3/100). The ST Score is a data-driven signal, not a recommendation.
What are DNLI's factor grades?
Valuation C, Profitability C+, Financial Strength B-, Momentum C+, Growth D, Forecast B+.
What is DNLI's valuation grade?
Denali Therapeutics Inc. (DNLI) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is DNLI's growth grade?
Denali Therapeutics Inc. (DNLI) earns a growth grade of D, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is DNLI's profitability grade?
Denali Therapeutics Inc. (DNLI) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is DNLI's financial strength grade?
Denali Therapeutics Inc. (DNLI) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for DNLI?
The average analyst price target for Denali Therapeutics Inc. (DNLI) is $33.67 from 19 analysts, which is +64.5% versus the recent price of $20.47.
What is DNLI's Piotroski score?
Denali Therapeutics Inc. (DNLI) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.